Drug intelligence / Profile preview

mAb8

Development stage: Preclinical
Lead developer: Stainwei Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

mAb8 is a preclinical-stage monoclonal antibody currently under development by Stainwei Biotechnology (Suzhou Stainwei Biotech Inc.). According to the company's internal pipeline, the candidate is being explored for a "new indication" (新适应症), although the specific biological target and therapeutic area have not been publicly disclosed. As a monoclonal antibody, it is likely designed to bind to a specific antigen to modulate a disease process, following the company's focus on oncology and inflammatory conditions.

Beyond the preview

Go deeper on mAb8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb8.

Explore the full profile